Lumenis has announced that Health Canada has authorized OptiLIFT and its proprietary Dynamic Muscle Stimulation (DMSt) technology for reducing signs and symptoms of evaporative dry eye disease, while also improving lower lid laxity and blinking mechanism. According to the company, the approval makes Lumenis the first to offer a muscle stimulation device in Canada cleared for ophthalmic use.
Quick Take
Health Canada has authorized Lumenis OptiLIFT and its proprietary Dynamic Muscle Stimulation (DMSt) technology for the treatment of evaporative dry eye disease. This approval marks the first time a muscle stimulation device has been cleared for ophthalmic use in Canada, specifically targeting lower lid laxity and the blinking mechanism to alleviate ocular surface symptoms.
Why It Matters
Traditional dry eye therapies often focus on tear chemistry or meibomian gland obstruction, but OptiLIFT addresses the mechanical and structural contributors to evaporative DED. By targeting eyelid laxity and blink efficiency through muscle stimulation, this technology offers a novel approach to patients whose symptoms are driven by poor lid apposition or functional blink deficits. For Canadian practitioners, this adds a unique, non-surgical tool to the dry eye armamentarium that bridges the gap between ocular surface health and periocular muscle function.
Key Details
Practice Implications
Clinicians should consider OptiLIFT for patients with evaporative dry eye who exhibit signs of eyelid laxity or incomplete blinking. This technology provides a clinical pathway to rehabilitate periocular muscle function, potentially improving the efficacy of concurrent treatments like IPL or thermal pulsation by ensuring a more functional blink and better lid-to-globe contact.
Who's Affected
What's Next
With Health Canada approval secured, Canadian eye care providers can expect the rollout of OptiLIFT into the commercial market. Future clinical updates may provide more granular data on how DMSt compares to or complements existing dry eye protocols in long-term symptom management.
AI-generated summary — always read the original source for full context
No comments yet. Be the first to share your thoughts.
